XML 11 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Operating expenses              
Research and development $ (9,835,736) $ (1,938,812) $ (18,950,423) $ (3,830,463) $ (13,279,780) $ (8,358,043) $ (5,947,294)
General and administrative expenses         (2,509,859) (1,233,876) (1,739,815)
Selling, general and administrative (6,475,430) (429,467) (7,284,196) (757,410)      
Other expenses (37,123) 0 (37,123) 0      
Loss from operations (16,348,289) (2,368,279) (26,271,742) (4,587,873) (15,789,639) (9,591,919) (7,687,109)
Change in fair value of derivative liabilities 4,132,525 0 4,132,525 0      
Financial and foreign exchange gain/(loss), net 563,854 (46,347) 986,566 (43,873) (77,147) (34,023) 1,590
Loss before income taxes (11,651,910) (2,414,626) (21,152,651) (4,631,746) (15,866,786) (9,625,942) (7,685,519)
Income tax benefit/(expense) (129,708) 0 (129,708) 0 0 0 0
Net income (loss) $ (11,781,618) $ (2,414,626) $ (21,282,359) $ (4,631,746) $ (15,866,786) $ (9,625,942) $ (7,685,519)
Weighted average number of shares outstanding basic 248,989,790 220,000,000 234,574,977 220,000,000      
Weighted average number of shares outstanding diluted 248,989,790 220,000,000 234,574,977 220,000,000      
Net income (loss) per share basic $ (0.05) $ (0.01) $ (0.09) $ (0.02)      
Net income (loss) per share diluted $ (0.05) $ (0.01) $ (0.09) $ (0.02)